NASDAQ:APVOAptevo Therapeutics Stock Price, Forecast & News

Aptevo Therapeutics' stock was trading at $0.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, APVO stock has increased by 2,085.7% and is now trading at $9.18. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aptevo Therapeutics.

Aptevo Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Aptevo Therapeutics.

Aptevo Therapeutics Inc (NASDAQ:APVO) released its quarterly earnings data on Wednesday, May, 13th. The biotechnology company reported ($2.84) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($2.35) by $0.49. Aptevo Therapeutics had a negative net margin of 102.54% and a negative return on equity of 224.05%. View Aptevo Therapeutics' earnings history.

1 brokers have issued 1 year price targets for Aptevo Therapeutics' stock. Their forecasts range from $3.00 to $18.50. On average, they expect Aptevo Therapeutics' stock price to reach $10.75 in the next year. This suggests a possible upside of 17.1% from the stock's current price. View analysts' price targets for Aptevo Therapeutics.

News articles about APVO stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aptevo Therapeutics earned a media sentiment score of 1.9 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Aptevo Therapeutics.

Some companies that are related to Aptevo Therapeutics include Theratechnologies (THERF), Genprex (GNPX), OASMIA PHARMACE/ADR (OASM), Eton Pharmaceuticals (ETON), Savara (SVRA), Axovant Gene Therapies (AXGT), Recro Pharma (REPH), Checkpoint Therapeutics (CKPT), Aptorum Group (APM), TFF Pharmaceuticals (TFFP), ContraFect (CFRX), SUMMIT THERAPEU/S (SMMT), Otonomy (OTIC), Xeris Pharmaceuticals (XERS) and Galmed Pharmaceuticals (GLMD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Amarin (AMRN), Axsome Therapeutics (AXSM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and Netflix (NFLX).

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of APVO stock can currently be purchased for approximately $9.18.

Aptevo Therapeutics has a market capitalization of $29.68 million and generates $32.42 million in revenue each year. The biotechnology company earns $-40,450,000.00 in net income (profit) each year or ($15.27) on an earnings per share basis. Aptevo Therapeutics employs 118 workers across the globe.

The official website for Aptevo Therapeutics is www.aptevotherapeutics.com.

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected]